The All Wales Medicines Strategy Group has published a recommendation regarding saxagliptin, the DPP-4 inhibitor (Onglyza®)
Saxagliptin is recommended as an option for use within NHS Wales for the treatment of adult patients aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with insulin (with or without metformin) when this regimen alone with diet and exercise does not provide adequate glycaemic control.
This advice is based on:
- An appraisal of evidence submitted in an assessment report, and
- A response submitted by the manufacturer
- Clinical expert opinion
- Patient and carer input.
The full text can be accessed from the link below:
All Wales Medicines Strategy Group Final Appraisal Recommendation – 2012: Saxagliptin (Onglyza®), July 2012
The assessment report underpinning this recommendation is:
AWMSG Secretariat Assessment Report – Advice No. 2012: Saxagliptin (Onglyza®), June 2012
A summary of the clinical expert opinion is also available online.
Read more about DPP-4 inhibitors on The Diabetes Elf.